OXUR Fundamental Analysis - OXURION NV

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to OXUR. OXUR was compared to 83 industry peers in the Biotechnology industry. Both the profitability and financial health of OXUR have multiple concerns. OXUR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year OXUR was profitable.

OXUR had a negative operating cash flow in the past year.

In the past 5 years OXUR reported 4 times negative net income.

In the past 5 years OXUR always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 39.34%, OXUR belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	39.34%
ROE	N/A
ROIC	N/A

ROA(3y)-183.9%

ROA(5y)-157.58%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 97950.00%, OXUR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

OXUR's Operating Margin of 45050.00% is amongst the best of the industry. OXUR outperforms 100.00% of its industry peers.

		Industry Rank	Sector Rank
OM	45050%
PM (TTM)	97950%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

OXUR does not have a ROIC to compare to the WACC, probably because it is not profitable.

OXUR has more shares outstanding than it did 1 year ago.

The number of shares outstanding for OXUR has been increased compared to 5 years ago.

The debt/assets ratio for OXUR is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -27.36, we must say that OXUR is in the distress zone and has some risk of bankruptcy.

OXUR has a Altman-Z score of -27.36. This is amonst the worse of the industry: OXUR underperforms 80.72% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-27.36

ROIC/WACCN/A

WACC1.81%

2.3 Liquidity

A Current Ratio of 0.17 indicates that OXUR may have some problems paying its short term obligations.

OXUR's Current ratio of 0.17 is on the low side compared to the rest of the industry. OXUR is outperformed by 92.77% of its industry peers.

A Quick Ratio of 0.17 indicates that OXUR may have some problems paying its short term obligations.

OXUR has a Quick ratio of 0.17. This is amonst the worse of the industry: OXUR underperforms 92.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.17
Quick Ratio	0.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 101.88%, which is quite impressive.

Looking at the last year, OXUR shows a very negative growth in Revenue. The Revenue has decreased by -97.62% in the last year.

Measured over the past years, OXUR shows a very negative growth in Revenue. The Revenue has been decreasing by -76.22% on average per year.

EPS 1Y (TTM)101.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%84.92%

Revenue 1Y (TTM)-97.62%

Revenue growth 3Y-86.15%

Revenue growth 5Y-76.22%

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.01, the valuation of OXUR can be described as very cheap.

Compared to the rest of the industry, the Price/Earnings ratio of OXUR indicates a rather cheap valuation: OXUR is cheaper than 100.00% of the companies listed in the same industry.

When comparing the Price/Earnings ratio of OXUR to the average of the S&P500 Index (27.19), we can say OXUR is valued rather cheaply.

		Industry Rank	Sector Rank
PE	0.01
Fwd PE	N/A

4.2 Price Multiples

OXUR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. OXUR is cheaper than 85.54% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	11.66

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for OXUR!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

OXURION NV

EBR:OXUR (1/9/2026, 7:00:00 PM)

0.0076

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-30 2025-09-30

Earnings (Next)04-03 2026-04-03/amc

Inst Owners0.22%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap475.76K

Revenue(TTM)2.00K

Net Income(TTM)1.96M

Analysts42.22

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	0.01
Fwd PE	N/A
P/S	237.88
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	11.66

EPS(TTM)0.61

EY8026.32%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0

BVpS-0.19

TBVpS-0.19

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	39.34%
ROE	N/A
ROCE	-7.59%
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	45050%
PM (TTM)	97950%
GM	N/A
FCFM	N/A

ROA(3y)-183.9%

ROA(5y)-157.58%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	4.92
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.17
Quick Ratio	0.17
Altman-Z	-27.36

F-Score4

WACC1.81%

ROIC/WACCN/A

Cap/Depr(3y)1.58%

Cap/Depr(5y)3.23%

Cap/Sales(3y)3.43%

Cap/Sales(5y)3.77%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)101.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%84.92%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-97.62%

Revenue growth 3Y-86.15%

Revenue growth 5Y-76.22%

Sales Q2Q%-100%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y112.45%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y87.88%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y87.87%

OCF growth 3YN/A

OCF growth 5YN/A

OXURION NV / OXUR.BR FAQ

What is the ChartMill fundamental rating of OXURION NV (OXUR.BR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OXUR.BR.

What is the valuation status for OXUR stock?

ChartMill assigns a valuation rating of 3 / 10 to OXURION NV (OXUR.BR). This can be considered as Overvalued.

Can you provide the profitability details for OXURION NV?

OXURION NV (OXUR.BR) has a profitability rating of 3 / 10.

Can you provide the financial health for OXUR stock?

The financial health rating of OXURION NV (OXUR.BR) is 0 / 10.

OXURION NV (OXUR.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

OXURION NV / OXUR.BR FAQ

What is the ChartMill fundamental rating of OXURION NV (OXUR.BR) stock?

What is the valuation status for OXUR stock?

Can you provide the profitability details for OXURION NV?

Can you provide the financial health for OXUR stock?